ReviewJournal of personalized medicine2019
Colorectal Cancer Biomarkers in the Era of Personalized Medicine.
Review in Journal of personalized medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- LncRNA MALAT1 as diagnostic and prognostic biomarker in colorectal cancers: A systematic review and meta-analysis.PloS one · 2024Pooled it
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors.Innovation (Cambridge (Mass.)) · 2024Article
- Loss ofEcancermedicalscience · 2024Article
- Identification of Novel Biomarkers for Response to Preoperative Chemoradiation in Locally Advanced Rectal Cancer with Genetic Algorithm-Based Gene Selection.Journal of gastrointestinal cancer · 2023Article
- By characterizing metabolic and immune microenvironment reveal potential prognostic markers in the development of colorectal cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Role of salt‑inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells.Molecular medicine reports · 2021Article
- Molecular testing for colorectal cancer: Clinical applications.World journal of gastrointestinal oncology · 2021Review
- The inflammatory pathogenesis of colorectal cancer.Nature reviews. Immunology · 2021Review
- YY1 Silencing Induces 5-Fluorouracil-Resistance andInternational journal of molecular sciences · 2021Article
- Systems-level biomarkers identification and drug repositioning in colorectal cancer.World journal of gastrointestinal oncology · 2021Review
- Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.Virchows Archiv : an international journal of pathology · 2021Article
- Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma.Frontiers in immunology · 2021Article
- What is the gut feeling telling us about physical activity in colorectal carcinogenesis?World journal of clinical cases · 2020Review
- Biomarkers in Colorectal Cancer: Current Research and Future Prospects.International journal of molecular sciences · 2020Review
- Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.Radiology and oncology · 2020Review
- Interaction between linc01615 and miR-491-5p regulates the survival and metastasis of colorectal cancer cells.Translational cancer research · 2020Article
- Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.International journal of molecular sciences · 2019Article
- Image-Based Network Analysis of DNp73 Expression by Immunohistochemistry in Rectal Cancer Patients.Frontiers in physiology · 2019Article
- Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.Technology in cancer research & treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory setting, which appears to benefit a small proportion of patients. Until recently, rat sarcoma (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.